Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Amylin Pharmaceuticals, Inc.
Data presented on phase II study of pramlintide
July 6th, 2005
Amylin Pharmaceuticals, Inc., (AMLN) presented detailed data from a 16-week phase II obesity study of pramlintide (AC137) at the European Congress on Obesity (ECO) in Athens, Greece. Pramlintide is a synthetic analog of human amylin, a hormone known to play a role in the regulation of appetite and food intake. The study showed statistically significant, progressive weight loss of 3.6% (3.5 kilograms) compared to placebo, with no evidence of a plateau in effect at 16 weeks. The weight loss was accompanied by a significant, progressive reduction in waist circumference, a recognized marker of abdominal obesity and cardiovascular risk. This blinded,...
Source: Biotech Week (2005-07-06)
|
